Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study

BACKGROUND: Immune-mediated diarrhea and colitis (IMDC) can limit immune checkpoint inhibitors (ICIs) treatment, which is efficacious for advanced malignancies. Steroids and infliximab are commonly used to treat it. These agents induce systemic immunosuppression, with its associated morbidity. We as...

Descripción completa

Detalles Bibliográficos
Autores principales: Abu-Sbeih, Hamzah, Ali, Faisal S., Alsaadi, Dana, Jennings, Joseph, Luo, Wenyi, Gong, Zimu, Richards, David M., Charabaty, Aline, Wang, Yinghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280383/
https://www.ncbi.nlm.nih.gov/pubmed/30518410
http://dx.doi.org/10.1186/s40425-018-0461-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280383/
https://www.ncbi.nlm.nih.gov/pubmed/30518410
http://dx.doi.org/10.1186/s40425-018-0461-4

Ejemplares similares